[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 618
Citations 0
Invited Commentary
April 2015

Market Exclusivity for Top-Selling PharmaceuticalsToo Long, Too Short, or Just Right?

Author Affiliations
  • 1Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Connecticut
  • 2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
JAMA Intern Med. 2015;175(4):637-638. doi:10.1001/jamainternmed.2014.7972

After the US Food and Drug Administration (FDA) approves a new brand-name prescription drug, the drug is protected from generic competition by the combination of 2 market exclusivity mechanisms. Patents cover the intellectual property inherent in the design of a new drug, processes used in manufacturing the medication, and sometimes the application of the drug to clinical practice. Patents last 20 years from the time they are issued, which is usually at least several years before a drug receives FDA approval. Exclusivity, which the FDA grants, supplements patents to ensure that all new drugs have a period of market exclusivity regardless of when their patents were issued.

First Page Preview View Large
First page PDF preview
First page PDF preview
×